RANK/RANKL expression in prostate cancer

Bone is the most common metastatic site in patients with prostate cancer. Skeletal-related events consisting of pathological fracture, spinal cord compression, and intractable pain are causes of a reduced quality of life for patients [1], [2]. Denosumab (XGEVA), a human monoclonal antibody against receptor activator of nuclear factor kappa B ligand (RANKL), was found to be a new therapeutic option for bone metastasis [3], [4], [5].